2024-06-30 09:00:00 ET
Summary
- VRNA received FDA approval for ensifentrine (Ohtuvayre) for the maintenance treatment of COPD on June 26.
- SNY/REGN's Dupixent represents a potential competitor. As do other drugs in development from SNY/REGN and GSK.
- Verona has the potential for further growth beyond the current approval, although in the near-term, initial sales seem likely to be a major determinant of the stock's direction.
...
Read the full article on Seeking Alpha
For further details see:
Verona Pharma Is Launching Ohtuvayre, Although There Will Be Competition